Making sure that youre talking to people about your problems, whether its a family member or a licensed professional, I think goes a long way, he said
Additional studies in cynomolgus monkeys have confirmed the potent dose-dependent, weight-lowering effects of chronic GLP-1R/GcgR co-agonism [78], supporting the translational promise of this novel balanced agonism for obesity and type 2 diabetes
Nachawi N, Rao PP, Makin V
AstraZeneca, Viking Therapeutics, Structure Therapeutics, and Roche are all initiating or advancing Phase 3 studies in 2026
A Brief Recap: Why This Matters For readers encountering this topic for the first time, the underlying issue is worth restating briefly
The FDA approved semaglutide for weight management in 2021 under the brand name Wegovy, while tirzepatide received approval in 2022 under the brand name Zepbound